Antiretroviral regimens containing the fusion inhibitor enfuvirtide (ENF) are associated with sustained viral suppression and immunological benefit. However, local injection site reactions (ISR) occur in the majority of patients. The aim of this study was to determine the pathogenesis of ISRs.
Methods
Injection sites were evaluated prospectively from 30 min up to 15–30 days post-injection in ENF-experienced (Cohort I) and ENF-naive patients (Cohort II) during the first 2 weeks of therapy. Four to five injections were given in rotating abdominal sites by a nurse using a standardized technique and were rigorously evaluated.
Results
Reactions were observed in 80–100% of patients; the majority of the reactions were mild to moderate, generally appeared within 24–48 h post-injection, and pain, induration and erythema were the most common clinical signs. Whereas most patients experienced ISRs, the overall prevalence in Cohort II was low (35% maximum). Punch biopsies of injection sites in Cohort I consisted primarily of mixed lymphocytic infiltrates with eosinophils and neutrophils. Injection vehicle (ENF buffer minus ENF) and reduced volume (2x0.5 ml ENF [45 mg] versus 1.0 ml [90 mg] ENF) were investigated in Cohort II. Fewer reactions appeared with vehicle and pain was absent with the smaller injection volume. Pathology was indistinguishable between ENF, vehicle and normal tissue in Cohort II patients.
Conclusion
These results suggest that injection technique, injection volume and peptide may influence ISR to ENF.
References
1.
KilbyJ.M., HopkinsS., VenettaT.M.Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.Nat Med1998; 4: 1302–1307.
2.
WildC., GreenwellT., MatthewsT.A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion.AIDS Res Hum Retroviruses1993; 9: 1051–1053.
3.
ChurchJ.A., HughesM., ChenJ.Pediatric AIDS Clinical Trials Group P1005 Study Team. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children.Pediatr Infect Dis J2004; 23: 713–718.
4.
KatlamaC., ArastéhK., ClotetB.Enfuvirtide TORO studies: 48 week results confirm 24 week findings.2nd International AIDS Society Meeting. 13–16 July 2003, Paris, France. Abstract LB2.
5.
KilbyJ.M., LalezariJ.P., EronJ.J.The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.AIDS Res Hum Retroviruses2002; 18: 685–693.
6.
LalezariJ.P., HenryK., O'HearnM.TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.N Engl J Med2003; 348: 2175–2185.
7.
LalezariJ.P., DeJesusE., NorthfeltD.W.A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.Antivir Ther2003; 8: 279–287.
8.
LalezariJ.P., EronJ.J., CarlsonM.A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.AIDS2003; 17: 691–698.
9.
ArastehK., LazzarinA., ClotetB.TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with n optimized background regimen.The XV International AIDS Conference. 11–16 July 2004. Bangkok, Thailand. Abstract MoOrB1058.
10.
LalezariJ.P., PatelI., ZhangX.Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1 infected subjects.J Clin Virol2003; 28: 217–222.
11.
WalmsleyS., HenryK., KatlamaC.Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.J Infect Dis2003; 188: 1827–1833.
12.
BallR.A., KinchelowT.Pathology of injection site reactions with enfuvirtide.J Am Acad Dermatol2003; 49: 826–831.
13.
Allergy: Principles and Practice. Edited by Middleton. St Louis: Mosby-Year Book, Inc, 1998.
14.
ZeltserR., ValleL., TanckC., HolystM.M., RitchlinC., GaspariA.A.Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein.Arch Dermatol2001; 137: 893–899.
15.
MaggiP., LadisaN., CinoriE., AltobellaA., PastoreG., FiloticoR.Cutaneous injection site reactions to long-term therapy with enfuvirtide.J Antimicrob Chemother2004; 53: 678–681.
